...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!

If you think this is a good agreement for shareholders, then I'm glad if you're happy! Go celebrate it! We have seen fantastic research by our scientists in both companies over the many years that we've been here, but it hasn't translated into real wealth creation here! In fact, the financings keep getting done at lower and lower prices. If that makes sense to you - considering "we're the world leaders in this field" and we just witnessed what Constellation went for and how we've advanced the development of Zen-3694 significantly - well then, why pop your balloon?

The current stock price is not surprising to me because the market doesn't pay up today for events that are likely years down the road (the registration enabling studies). And the licensing agreement is about what I'd expect at this time. Of course, all that gets morphed into me being happy happy happy with the current situation.  Would I like to see us get bought out today for big $$$$?  Of course.  That's just not the reality of where we are as I see it. Maybe I'm wrong and something big will happen in the near term.  I just don't see that as a high probability.

Share
New Message
Please login to post a reply